EuroSIDA

EuroSIDA
Name	EuroSIDA
Established	1994
Type	observational cohort
Location	Europe
Participants	People living with HIV
Coordinating center	Copenhagen HIV Programme
Scope	Multinational

EuroSIDA

EuroSIDA is a multicenter observational cohort study monitoring people living with HIV across Europe, with additional sites in Argentina, Israel, Russia, and Ukraine. It links clinical outcomes, antiretroviral treatment patterns, and coinfection data to inform public health policy and clinical practice in contexts such as the HIV pandemic, antiretroviral therapy rollout, and comorbidity management. The study fosters collaboration among leading institutions and investigators from academic centers, public health agencies, and specialty clinics.

Overview

EuroSIDA is an observational cohort that collects longitudinal clinical, laboratory, and treatment data from patients attending outpatient clinics in multiple countries. Participating institutions include major hospitals and research centers across Western Europe, Central Europe, Eastern Europe, Scandinavia, and beyond, bringing together clinicians from University College London, Karolinska Institutet, University of Copenhagen, University of Barcelona, Ghent University, Charité – Universitätsmedizin Berlin, and Pitié-Salpêtrière Hospital. The cohort examines outcomes such as AIDS-defining illnesses, non-AIDS events, antiretroviral toxicity, hepatitis coinfections, and malignancies, linking findings to guideline bodies like European AIDS Clinical Society, World Health Organization, and regional public health agencies.

History and development

EuroSIDA was initiated in the mid-1990s amid the rising use of combination antiretroviral therapy and the evolving landscape of HIV care in Europe. Early collaborations involved investigators associated with networks such as the EuroCoord and national surveillance programs from countries including United Kingdom, France, Germany, Spain, Italy, Sweden, and Denmark. Over time the study expanded to include sites in Russia, Ukraine, Belarus, Argentina, and Israel, reflecting shifts in epidemiology and treatment access. The cohort adapted to major developments such as the introduction of protease inhibitors, integrase inhibitors, and strategies endorsed by panels like the U.S. Department of Health and Human Services and trials conducted by groups including INSIGHT and START.

Study design and methodology

EuroSIDA employs a prospective cohort design with standardized case-report forms and centralized data management. Clinical variables encompass demographics, CD4 cell counts, plasma HIV-1 RNA, antiretroviral regimens, opportunistic infections, and laboratory markers for coinfections like hepatitis B and hepatitis C, integrating diagnostic criteria from authorities such as Centers for Disease Control and Prevention and classification systems used in trials by National Institutes of Health. Sites submit anonymized patient-level data to a coordinating center using quality-control procedures informed by practices at institutions like European Medicines Agency and biostatistical methods drawn from collaborations with biostatisticians at Imperial College London and McGill University. Substudies incorporate stored plasma and peripheral blood mononuclear cells enabling biomarker analyses in partnership with laboratories at Karolinska University Hospital and translational groups linked to Wellcome Trust–funded programs.

Key findings and impact

EuroSIDA has produced influential results on the natural history of HIV and the effects of antiretroviral therapy across diverse settings. Publications from the cohort informed understanding of mortality trends following the expansion of combination therapy in the 1990s and 2000s, echoing findings from cohorts like Swiss HIV Cohort Study and Danish HIV Cohort. EuroSIDA data clarified risks of cardiovascular disease, liver-related mortality in the context of hepatitis C coinfection, incidence of non-AIDS malignancies, and predictors of treatment failure, influencing guideline updates by bodies such as the European AIDS Clinical Society and recommendations similar to those by British HIV Association. The cohort’s analyses on geographic disparities contributed to policy discussions involving the European Centre for Disease Prevention and Control and helped shape capacity-building initiatives in Eastern Europe and Central Asia supported by agencies including UNAIDS and World Bank.

Collaborating sites and governance

EuroSIDA’s network includes university hospitals, infectious disease clinics, and public health institutes across participating countries, coordinated through a steering committee comprising clinicians and epidemiologists affiliated with University of Oxford, University of Amsterdam, University of Vienna, and Moscow State University collaborators. Governance structures integrate data access committees, ethics oversight with institutional review boards at centers such as Hospital Clinic of Barcelona and Helsinki University Hospital, and collaborative working groups addressing cardiovascular disease, liver disease, and coinfections coordinated with specialty societies like the European Society of Clinical Microbiology and Infectious Diseases.

Funding and ethics

Funding for EuroSIDA has come from a combination of academic grants, governmental research councils, and foundations including grants linked to European Commission framework programs, philanthropic support from organizations such as the Wellcome Trust, and project-specific funding related to hepatitis and cancer research. Ethical oversight aligns with national regulations and international standards referenced by institutions like World Medical Association and research ethics committees at participating centers; patient consent procedures and data protection adhere to principles comparable to those in General Data Protection Regulation–aligned frameworks and institutional review panels in each jurisdiction.

Category:Cohort studies